Harbin, China, 15 July 2021 – Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®) recently participated in the virtual 16th Ice City Conference of Cardiology (ICC2021), presenting two real-time surgical operations using Firehawk® Rapamycin Target Eluting Coronary Stent System (Firehawk®) and Firefighter™ PTCA Balloon Dilatation Catheter (Firefighter™) in complex lesions, respectively. The conference was co-organized by Heilongjiang Medical Association and Heilongjiang Cardiology Society, and assisted by the Second Hospital Affiliated to Harbin Medical University and the Cardiovascular Disease Branch of Heilongjiang Medical Association.
Prof. Yu Li from Beijing Anzhen Hospital shared a realt-time surgical operation case of combined use of Firehawk® in calcified bifurcation lesions. According to Prof. Li, the adoption of single-sided groove design and targeted drug-release technology allows Firehawk® stents to achieve the "gold standard" efficacy with only 1/3 of the drug loading of similar products – the lowest in the world. At the same time, Firehawk® stent has a complete coverage rate of 99.9%, which is highly safe and can reduce the occurrence of adverse events. Prof. Li also mentioned that for complex multifractional lesions, it is crucial to choose a suitable stent with strong support, good crossability, and good long-term prognosis for patients, all of which can be achieved by Firehawk® to meet patients’ needs.
Prof. Zongtao Wang from the First Affiliated Hospital of Guangdong Pharmaceutical University shared a case of Firehawk® stent in a severe calcified lesion. Prof. Wang stated that Firehawk® showed excellent crossability in a high-resistance lesion. In addition, the excellent performance of Firehawk® in surgical procedures was widely recognized by surgeons and experts attending the Conference.
In the real-time surgery using Firefighter™ PTCA Balloon Dilatation Catheter in complex Lesions, Professor Jingang Cui from the Fuwai Hospital, affiliated to the National Cardiovascular Center, shared the clinical application of this product. According to Professor Cui, Firefighter™ PTCA balloon dilatation catheters are semi-compliant balloons specially designed for complex lesions, with the characteristics of being small, durable, fitting, and smooth. The extremely thin outer diameter allows for anastomotic manipulation within a 6F catheter, making it less prone to guidewire entanglement during multi-device manipulation. The new combination of patented fluorine-containing inner and outer catheters can avoid folding of the guidewire opening, which enhances the safety of operations. The catheters also have high pressure resistance and excellent crossability, which is conducive to the treatment of complex diseases in clinical use. After the live broadcast of the surgery, Professor Cui shared two cases that demonstrated excellent performance of Firefighter™ PTCA Balloon Dilation Catheters in CTO lesions.
Prof. Bingchen Liu from the Fourth Hospital of Harbin Medical University shared a case of inadequate pretreatment of a calcified lesion resulting in poor stent expansion. Based on his surgical experience, Professor Liu chosen Firefighter™ NC high-pressure non-compliant balloon for post-dilatation treatment. During operation, the balloon reached up to 28 atm, allowing the lesion to expand smoothly. Firefighter™ NC is a new generation of high-pressure resistant and rapid exchange balloon dilatation catheters developed by MicroPort®, following its predecessor, Foxtrot™ NC. The outer surface of the catheter is coated with a hydrophilic polymer from the front and rear attachment points to the distal end of the product, which reduces friction on the surface of the catheter when combined with water during surgery, thereby facilitating catheter delivery into and across lesions. The product is suitable for balloon dilation of coronary artery stenosis sites or coronary bypass bridge stenosis sites to improve myocardial perfusion. It is also suitable for post-balloon dilation of stents after their implantation.
Attracting more than 400 experts and scholars from home and abroad, ICC2021 provided a great opportunity for medicine practitioners in the field of heart and cardiovascular disease treatment to exchange ideas with each other during the pandemic. In the future, MicroPort® will continue to help spread academic cutting-edge information, share clinical experiences, promote academic exchanges in the field of cardiovascular diseases, and provide more total solutions that can prolong and reshape the lives for all patients.